The potentially functional polymorphism, rs763110 (À844C4T), in the promoter region of the FAS ligand (FASL) gene, has been implicated in cancer risk, but individually published studies show inconclusive results. To derive a more precise estimation of the association between the FASL rs763110 and risk of cancer, we performed a meta-analysis of 19 published studies that included 11 105 cancer cases and 11 372 controls. We used odds ratios (ORs) and 95% confidence intervals (CIs) to assess the strength of the associations. Overall, the rs763110 CT and TT variant genotypes were associated with a significantly reduced cancer risk of all cancer types in different genetic models (homozygote comparison: OR ¼ 0.80, 95% CI: 0.68-0.95, P heterogeneity ¼ 0.001; heterozygote comparison: OR ¼ 0.82, 95% CI: 0.72 -0.95, P heterogeneity o0.001; dominant model comparison: OR ¼ 0.82, 95% CI: 0.71 -0.94, P heterogeneity o0.001; and recessive model comparison: OR ¼ 0.88, 95% CI: 0.81 -0.96, P heterogeneity ¼ 0.074). In the stratified analyses, the risk remained for studies of the smoking-related cancers and Asian populations, or population-based studies in all the genetic models. Although some modest bias could not be eliminated, this meta-analysis suggests that the FASL rs763110 T allele has a possible protective effect on cancer risk.
Introduction
One of the major functions of human immune system is to eliminate potentially malignant cells, for which anticancer T lymphocytes play a crucial role in immunosurveillance of cancer cells. However, T lymphocytes can be triggered into an apoptosis process, also called activation-induced cell death (AICD). 1 Many studies indicate that AICD is an important mechanism responsible for the increased apoptosis rate among the tumor-infiltrating lymphocytes, leading to the transformed cells escaping the elimination by anticancer immunosurveillance and, therefore, AICD contributes to cancer development. 2, 3 Activation-induced cell death is a FAS ligand (FASL)-dependent process, and the increased expression of FASL can cause AICD in peripheral T cells. 4 Antigenic stimulation of cancer within the tumor microenvironment can induce tumor-infiltrating lymphocytes to overexpress FASL and subsequently lead to suicide or fratricide of tumor-infiltrating lymphocytes through the FAS -FASL interaction-triggered apoptosis. 5 In addition, mutations in death-receptor pathway genes may cause a reduced expression of FAS, but an increased expression of FASL, in cancers. 6, 7 Decreased expression of FAS may protect transformed cells from the elimination by anticancer immuneresponses, whereas increased FASL expression may enhance the ability of cancer cells to counterattack the immune system by killing FAS-sensitive lymphocytes, thereby contributing to cancer development. 8, 9 The human FASL gene (GenBank accession no: Z96050) is located on chromosome 1q23 and comprised of four exons. FASL can trigger cell-death signal cascade by crosslinking with FAS, and the FAS/FASL system plays a crucial role in modulating apoptosis and maintaining the homeostasis. 10 As shown in the HapMap and dbSNP databases, the FASL gene is highly polymorphic, but the most extensively studied polymorphism is the C to T substitution at position À844 (À844C4T, rs763110) in the promoter region of the FASL gene. This potentially functional polymorphism is located within a putative binding motif of CAAT/enhancer-binding protein b (C/EBP-b) transcription factor, and a considerably higher basal expression of FASL is associated with the FASL rs763110 C allele compared with the T allele. 11 As for other SNPs in the FASL gene, such as rs5030772, 12 there are relatively fewer studies reported to date. Thus, the sample size for these SNPs is too small for a meaningful metaanalysis. Therefore, we chose to perform a meta-analysis of the rs763110. Recently, many studies have investigated the role of the FASL rs763110 in the etiology of cancers of various organs, including the breast, 13 -15 cervix, 16 -19 bladder, 20 lung, 21 -23 head and neck, 12 skin, 24, 25 esophagus, 26 stomach, 27 ovary, 28 thymus, 29 and pancreas. 30 However, the results of these studies remain inconclusive. In this report, we performed a meta-analysis to estimate the effect of this polymorphism on cancer risk as well as to quantify the potential between-study heterogeneity.
Materials and methods
Identification and eligibility of relevant studies Two online electronic databases (PubMed and Embase) were searched (the last search update was 1 February 2009, using the search terms 'FAS ligand', 'FASL', 'TNFSF6', 'CD95L', 'polymorphism', and 'cancer'). The search was limited to English-language papers. We also used the PubMed option 'Related Articles' in each research article to search potentially relevant articles. Moreover, references of all included articles were also screened. Of the studies with the same or overlapping data published by the same investigators, we selected the most recent ones with the largest number of participants. Studies included in our meta-analysis have to meet the following inclusion criteria:
(1) use a case -control design and (2) contain available genotype frequency. Major reasons for exclusion of studies were: (1) no control population; (2) duplicate of earlier publication; and (3) no usable genotype frequency data.
Data extraction
Information was carefully extracted from all eligible publications independently by two of the authors, according to the inclusion criteria. Discrepancies were adjudicated by a third reviewer until consensus was achieved on every item. For each study, the following characteristics were collected: the first author's last name, year of publication, country of origin, ethnicity, matching conditions, numbers of genotyped cases and controls, source of control groups (population-or hospital-based controls), source of DNA, genotyping methods, and quality control. Different ethnic descents were categorized as European, Asian, and African.
Statistical analysis
The strength of the association between the FASL rs763110 and cancers was measured by odds ratios (ORs) with 95% confidence intervals (CIs). The statistical significance of the pooled OR was determined using the Z-test. We first estimated cancer risks associated with the CT and TT genotypes, compared with the wild-type CC homozygote, and then evaluated the risks associated with (TT/CT) vs CC and TT vs (CT/CC), assuming the dominant and recessive effects of the variant T allele, respectively. Stratification analyses were also performed by cancer types (if one cancer type contained less than three individual studies, it was combined into the 'other cancers' group), ethnicity, and source of controls. Lung, bladder, esophageal, head and neck, and pancreatic cancers were defined as smokingrelated cancers, because tobacco smoking is an established risk factor for these cancers. 26,31 -34 In addition, given the roles of estrogen level in the etiology of breast, cervical, and ovarian cancers, these cancers were defined as estrogen-related cancers. 35, 36 Then we examined whether the FASL rs763110 was associated with the risk of these cancers. Heterogeneity assumption was checked by the w 2 -based Q-test and considered significant when Po0.05. Both fixed-effects model using the Mantel -Haenszel method 37 and random-effects model using the DerSimonian and Laird method 38 were used to pool the results. Furthermore, the variables of ethnicities, cancer sites, sources of controls, and sample sizes were examined in a meta-regression model to explore the possible heterogeneity among different kinds of studies. The interstudy variance (t 2 ) was used to quantify the degree of heterogeneity between studies, and the percentage of t 2 was used to describe the extent of explained heterogeneity of the characteristics. 39 Sensitivity analyses were also performed to assess the stability of the results. Funnel plots and Egger's linear regression test were used to provide diagnosis of potential publication bias. 40 All analyses were carried out with SAS Figure 1 ). Notably, the T-variant genotypes (CT and TT) were associated with a decreased cancer risk in a dose-response manner compared with the CC genotype (OR ¼ 0.82, 95% CI: 0.72-0.95 for CT and 0.80, 0.68-0.95 for TT; P trend o0.001).
In the stratified analysis by cancer type, as shown in Table 2 , we found that individuals with the variant genotypes had a significantly lower risk of the 'other Figure 1) . Then, we divided these studies into two subgroups according to their sources of controls. For the studies with population-based controls, we found that the variant genotypes were associated with a significantly decreased cancer risk in all genetic models ( However, among studies with hospital-based controls, no significant association was observed in any genetic model (Table 2, Figure 3 ). By comparing with the variant T-allele frequency in controls between population-and hospital-based studies, we found that the T-allele frequency among controls in hospital-based studies (33.5%) was slightly higher than those in population-based studies (31.6%). These data suggested that those studies whose controls were selected from hospital may underestimate the cancer risk. Figure 3 Forest plot of cancer risk among studies with population-based controls associated with the FASL rs763110 polymorphism (TT/CT vs CC).
Test of heterogeneity
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI. 
Discussion
This meta-analysis, including 11 105 cases and 11 372 controls from 19 published case -control studies, explored the association between a potentially functional polymorphism, rs763110, within the FASL promoter region and cancer risk. We found that there was evidence that the variant genotypes of the rs763110 were associated with a significant decrease in overall cancer risk in a T-allele dose-response manner. This finding is biologically plausible.
Immune surveillance of T cells plays an essential role in maintaining homeostasis, 1, 42 and the AICD process of T cells is regulated by the FAS/FASL system. Genetic variations of crucial genes in this cell-death pathway may thus influence susceptibility to cancers. The FASL rs763110 has been shown to have a substantial impact on the promoter activity of the FASL gene in an in vitro assay system, because the variant affects a binding motif for the transcription factor C/EBP. A considerably higher basal expression of FASL is associated with the FASL rs763110 C allele compared with the T allele. 11 It has been shown that the FASL rs763110 C allele, which had a higher expression of FASL in T cells, was associated with an enhanced rate of AICD in T cells, suggesting that the rs763110 C allele may be a risk allele for cervical cancer. 16 AICD of T lymphocytes may help malignant cells to escape from killing by natural killing cells. 1, 3 The C to T change at the FASL rs763110 polymorphic site strongly reduces the expression of FASL, and consequentially reduces AICD of tumor-specific T cells in response to malignant cells, which may result in more powerful immune surveillance and reduce susceptibility to cancer risk among individuals carrying the T allele. 16 In our present meta-analysis, we found that individuals with the TT genotype were associated with a lower cancer risk than participants with the CC genotype, which was consistent with experimental findings. Tobacco smoke contains hundreds of chemicals some of which are carcinogens, such as polycyclic aromatic hydrocarbons and N-nitroso compounds, as evidenced in animal studies. 43 Tobacco smoking is a well-established risk factor for cancers of many organs, including lung, bladder, esophagus, head and neck, and pancreas. 26,31 -34 Besides, studies have also shown that chronic smoking could enhance the FASL expression in peripheral blood lymphocytes, which is believed to impair the immune function in smokers. 44 Moreover, transformed cells resulting from exposure to tobacco carcinogens may evade tumor-infiltrating lymphocyte killing to become malignant because of high expression of FASL. 45 Although we found an evidence for the association between the FASL rs763110 T-variant genotypes and the reduced risk of smoking-related cancers, this was not evident for other cancers. This difference may be due to limited statistical power as a result of the small sample size and low-penetrance effects of this SNP in these nonsmoking-related cancers as well as possibly different Therefore, the effect of estrogen level on the risk may outweigh that of this FASL rs763110 in estrogen-related cancers. However, more studies are needed to validate the results of this meta-analysis for estrogen-related cancers.
We found an evidence for the association between the FASL rs763110 and cancer risk among Asians, but not Europeans, a possible reflection of differences in genetic background and gene -environment interactions in the etiology. For example, the T-allele frequency among controls was 0.29 in Asian populations and 0.36 in European populations, suggesting a possible ethnic difference. In addition, half (5/10) of the Asian studies focused on smoking-related cancers, whereas only two studies 12, 23 investigated smoking-related cancer in the European populations. However, there was no reported study in the African populations. Therefore, additional studies are warranted to further validate possible ethnic differences in the effect of this functional SNP on cancer risk.
We also found that the association was significant among studies using the population-based controls, but not the hospital-based controls. This may be because the hospitalbased studies have inherent selection biases due to the fact that such controls may not be representative of the study population or the general population, particularly when the genotypes under investigation were associated with the disease-related conditions that hospital-based controls may have. Thus, the use of proper and representative populationbased control participants is very important in reducing biases in such genotype association studies.
In this meta-analysis, three studies assessed the SNPs in the adjacent regions that were in linkage disequilibrium with rs763110 12, 15, 25 in which FASL haplotype and combined genotype analyses showed that the variant haplotypes were associated with significantly higher cancer risk. These results indicate that FASL polymorphisms may play a crucial role in the development of cancer, which is biologically plausible. In future, large, well-designed studies for haplotypes, along with combined analysis, are recommended.
Identifying the source of heterogeneity is one of the most important goals of the meta-analysis. Thus, we stratified the studies according to ethnicity, cancer type, source of controls, sample size, and genotyping method, and we found that several factors, such as ethnicity, cancer type, and genotyping method, may have contributed to the observed heterogeneity, which was further confirmed by meta-regression analyses.
Some limitations of this meta-analysis should be addressed. First, lack of the original data of the reviewed studies limited our further evaluation of potential interactions, because the interactions between gene -gene, gene -environment, and even different polymorphic loci of the same gene may modulate cancer risk. Second, misclassifications on disease status and genotypes may also influence the results, because cases in several studies were not confirmed by pathology or other gold standard methods, and the quality control of genotyping was also not well-documented in some studies. Third, the numbers of published studies were not sufficiently large for a comprehensive analysis, particularly for any given cancer site. In spite of these, our meta-analysis also had some advantages. First, substantial number of cases and controls were pooled from different studies, which significantly increased statistical power of the analysis. Second, the quality of case -control studies included in the current meta-analysis was satisfactory based on our selection criteria. Third, we did not detect any publication bias indicating that the whole pooled result may be unbiased.
In summary, this meta-analysis identified an evidence of the association between the FASL rs763110 and cancer risk, supporting the hypothesis that the FASL rs763110 may be a low-penetrance susceptibility marker of cancer. Our results also suggest that additional large studies are warranted to validate possible ethnic difference in the risk. Future studies should use standardized unbiased genotyping methods, homogeneous cancer patients, and well-matched controls with multi-ethnic groups. Moreover, gene -gene and gene -environment interactions should also be examined in the future analysis. These future studies should lead to better, comprehensive understanding of the association between the FASL rs763110 and cancer risk.
